<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id><journal-id journal-id-type="pmc">eid</journal-id><journal-title>Emerging Infectious Diseases</journal-title><issn pub-type="ppub">1080-6040</issn><issn pub-type="epub">1080-6059</issn><publisher><publisher-name>Centers for Disease Control</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11294725</article-id><article-id pub-id-type="pmc">2631707</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Economic impact of antimicrobial resistance.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>McGowan</surname><given-names>J. E.</given-names><suffix>Jr</suffix></name><email>jmcgowa@sph.emory.edu</email></contrib></contrib-group><aff>Emory University School of Medicine, Atlanta, Georgia, USA.</aff><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2001</year></pub-date><volume>7</volume><issue>2</issue><fpage>286</fpage><lpage>292</lpage><abstract><p>One reason antimicrobial-drug resistance is of concern is its economic impact on physicians, patients, health-care administrators, pharmaceutical producers, and the public. Measurement of cost and economic impact of programs to minimize antimicrobial-drug resistance is imprecise and incomplete. Studies to describe and evaluate the problem will have to employ new methods and be of large scale to produce information that is broadly applicable.</p></abstract></article-meta></front></article>